Exchange & Returns Information
Review Details
(0)
| Generic For | IRESSA |
|---|---|
| Active Ingredient | GEFITINIB |
| Strength | 250MG |
| Manufacturer | SAMARTH LIFE SCIENCES PVT LTD |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 2 BOXES - 60 TABLETS | $ 0.42 | $ 25.30 |
$ 21.51
Apply ZARVY26 (-15%)
You save $ 3.80
|
||
| 3 BOXES - 90 TABLETS | $ 0.39 |
8% $ 37.95
$ 35.00
|
$ 29.75
Apply ZARVY26 (-15%)
You save $ 5.25
|
||
| ★ Best Value 6 BOXES - 180 TABLETS | $ 0.35 |
18% $ 75.90
$ 62.60
|
$ 53.21
Apply ZARVY26 (-15%)
You save $ 9.39
|
Reference information will be available soon.
Unigef 250 is a generic formulation of gefitinib 250mg, a first-generation oral tyrosine kinase inhibitor (TKI) developed to selectively inhibit epidermal growth factor receptor (EGFR) activity in advanced non-small cell lung cancer (NSCLC).
By blocking EGFR-driven signaling pathways, it disrupts tumor cell proliferation and survival, making it a well-established first-line therapy for patients with EGFR mutation-positive lung adenocarcinoma.
Its oral formulation provides a convenient targeted treatment option, particularly valuable in personalized oncology approaches.
AntiCancer Drugs > Non-Small Cell Lung Cancer with EGFR Mutation
Indicated for the first-line treatment of advanced NSCLC harboring EGFR exon 19 deletion or exon 21 (L858R) mutations. Demonstrates significant improvement in progression-free survival, with particular effectiveness observed in never-smokers and Asian female patients with lung adenocarcinoma.
AntiCancer Drugs > EGFR-TKI Resistance Strategy
Utilized as part of sequential therapy in cases of T790M resistance. Upon disease progression, patients may transition to third-generation EGFR inhibitors such as osimertinib to overcome acquired resistance mechanisms.
AntiCancer Drugs > Off-label Solid Tumor Research
Studied in EGFR-overexpressing malignancies, including head and neck squamous cell carcinoma (HNSCC), pancreatic cancer, and other solid tumors, often within clinical trials or combination regimens exploring its broader therapeutic potential.
Gefitinib 250mg acts by reversibly binding to the intracellular tyrosine kinase domain of EGFR, thereby blocking ATP binding and interrupting downstream signaling cascades.
This results in the inhibition of tumor cell proliferation, suppression of angiogenesis, and reduction of metastatic potential in EGFR-dependent cancers, making it an effective targeted therapy in mutation-positive tumors.
Recommended Dose:
→ 250 mg orally once daily, with or without food
→ Continue until disease progression or unacceptable toxicity
Alternative Administration:
→ For patients unable to swallow tablets, disperse in 4–8 oz of noncarbonated water, stir for 15 minutes, and drink immediately
→ Rinse container and consume the residue
→ May also be administered via nasogastric tube
Patient Selection:
→ Use only in patients with EGFR exon 19 deletions or exon 21 L858R substitutions (tumor or plasma specimen) confirmed by validated testing
Monitoring:
→ Regularly assess liver function
→ Monitor for interstitial lung disease (ILD) signs
→ Check for dermatologic reactions
Store in a cool, dry place away from heat and moisture
Avoid direct sunlight and temperatures above 30°C
Keep the blister or bottle tightly closed
Keep out of reach of children
Common: diarrhea, rash, acne, dry skin, nausea, fatigue
Less common: elevated liver enzymes, interstitial lung disease, ocular disorders
Severe: pulmonary toxicity, hepatotoxicity → requires discontinuation and immediate medical attention
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
